Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cullinan Therapeutics to post earnings of ($0.80) per share and revenue of $5.5560 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 9, 2026 at 9:30 AM ET.

Cullinan Therapeutics Stock Up 2.1%

Shares of Cullinan Therapeutics stock opened at $12.44 on Thursday. Cullinan Therapeutics has a twelve month low of $5.68 and a twelve month high of $13.43. The business has a 50-day moving average price of $11.20 and a 200-day moving average price of $9.08. The firm has a market cap of $734.96 million, a price-to-earnings ratio of -3.76 and a beta of -0.09.

Insiders Place Their Bets

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 4,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $12.30, for a total value of $49,200.00. Following the transaction, the insider owned 128,635 shares of the company’s stock, valued at $1,582,210.50. This represents a 3.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jacquelyn L. Sumer sold 3,480 shares of Cullinan Therapeutics stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.67, for a total value of $33,651.60. Following the sale, the insider owned 135,432 shares of the company’s stock, valued at approximately $1,309,627.44. This trade represents a 2.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 33,836 shares of company stock worth $361,087. Corporate insiders own 7.16% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC bought a new position in Cullinan Therapeutics in the fourth quarter worth approximately $172,000. AlphaCentric Advisors LLC purchased a new stake in shares of Cullinan Therapeutics in the 4th quarter worth $197,000. Fox Run Management L.L.C. lifted its holdings in shares of Cullinan Therapeutics by 36.6% in the 4th quarter. Fox Run Management L.L.C. now owns 21,204 shares of the company’s stock worth $219,000 after buying an additional 5,676 shares during the period. Caption Management LLC grew its position in shares of Cullinan Therapeutics by 107.0% during the 3rd quarter. Caption Management LLC now owns 28,389 shares of the company’s stock worth $168,000 after buying an additional 435,062 shares in the last quarter. Finally, Magnetar Financial LLC purchased a new position in shares of Cullinan Therapeutics during the third quarter valued at $156,000. 86.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CGEM shares. New Street Research set a $26.00 price target on shares of Cullinan Therapeutics in a research note on Thursday, November 20th. BTIG Research increased their price target on shares of Cullinan Therapeutics from $32.00 to $38.00 and gave the company a “buy” rating in a report on Monday, November 24th. Morgan Stanley reiterated an “overweight” rating and issued a $30.00 price target on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Wedbush upped their price objective on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Finally, HC Wainwright lifted their target price on Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.33.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.